Cancer du sein : identification de biomarqueurs potentiels pour prédire l’efficacité du ribociclib

• Date :
• 6    
  0

Expert video report on triple negative breast cancer from ASCO 2020

• Date :
• 4    
  0

ASCO 2020 breast cancer roundup

• Date :
• 4    
  0

Brian Jonas, ASCO20: Venetoclax combination treatment in older patients with acute myeloid leukemia

• Date :
• 3    
  0

Expert video report on colorectal cancer from ASCO 2020

• Date :
• 3    
  0

L'essentiel de l'ASCO 2020

• Date :
• 2    
  0

Jared Weiss, ASCO20: Trilaciclib in Patients with Small Cell Lung Cancer

• Date :
• 1    
  0

PART 1: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients

• Date :
• 1    
  0

John Kuruvilla, ASCO20: Results of the KEYNOTE-204 Phase III Trial in Patients with cHL

• Date :
• 1    
  0

PART 2: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients

• Date :
• 1    
  0

Expert video report on lung cancer from ASCO 2020

• Date :
• 1    
  0

Expert video report on breast cancer biomarkers from ASCO 2020

• Date :
• 1    
  0

New Combination Therapy in the Treatment of Triple-Negative Breast Cancer

• Date :
• 1    
  0

ASCO Global Webinar Series: April 21, Laboratory Research & Screening Patients

• Date :
• 1    
  0

MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use

• Date :
• 1    
  0

PANDA: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT

• Date :
• 1    
  0

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients

• Date :
• 1    
  0

Cisplatin +/- veliparib in metastatic TNBC and/or germline BRCA-associated breast cancer

• Date :
• 1    
  0

Le programme CAPRI démontre l'efficacité du suivi à distance des traitements oraux

• Date :
• 0    
  0

Cancer du poumon : perspective de traitement par anticorps conjugué

• Date :
• 0    
  0

Résultats prometteurs d'une association de thérapies ciblées dans le gliome de l'enfant

• Date :
• 0    
  0

Sarcomes : allongement de la survie avec une bi-chimiothérapie

• Date :
• 0    
  0

New combination therapy in patients with MDS/CMML or LB AML

• Date :
• 0    
  0

Clinical Updates in Urothelial Carcinoma and Renal Cell Carcinoma

• Date :
• 0    
  0

Phase III KEYNOTE-177 Trial of Pembrolizumab in Metastatic Colorectal Cancer

• Date :
• 0    
  0

Neurological and Psychiatric Events in Patients with COVID-19

• Date :
• 0    
  0

Three-year Follow-up of the TRAIN-2 Phase III Trial

• Date :
• 0    
  0

Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma

• Date :
• 0    
  0

Results of the Phase III CLL14 Trial for Chronic Lymphocytic Leukaemia

• Date :
• 0    
  0

Bispecific Antibodies in the Treatment of Multiple Myeloma

• Date :
• 0    
  0

The Potential of CAR-T Treatment JNJ-4528 in Multiple Myeloma

• Date :
• 0    
  0

Updated Results from the Phase Ib/II CARTITUDE-1 Trial

• Date :
• 0    
  0

Interim Analysis of the Phase II OPTIC Trial of Ponatinib in CP-CML

• Date :
• 0    
  0

5-Year Analysis of the Phase II PACE Trial of Ponatinib in Ph+ leukemia

• Date :
• 0    
  0

Summary of the Phase 1 SPEARHEAD-1 Trial in Sarcoma

• Date :
• 0    
  0

Key findings of the KEYNOTE-355 study

• Date :
• 0    
  0

ESMO Expert video report on urothelial cancer from ASCO 2020

• Date :
• 0    
  0

ASCO Global Webinar Series July 28, Experiences and Lessons During the COVID-19 Pandemic

• Date :
• 0    
  0

ASCO Global Webinar Series: June 30, Learning Through Collaboration -- Population-Based Research

• Date :
• 0    
  0

ASCO Global Webinar Series: April 28, Using Telemedicine & Burnout

• Date :
• 0    
  0

ASCO Global Webinar Series: April 14, Experiences and Lessons During the COVID 19 Pandemic

• Date :
• 0    
  0

ASCO Global Webinar Series: May 5, Surgical Oncology & Clinical Research

• Date :
• 0    
  0

ASCO Global Webinar Series: May 12, Practice Plans for Transitioning Back to Standard Operations

• Date :
• 0    
  0

ASCO20 Virtual Education Program Special Session: ASCO Voices

• Date :
• 0    
  0

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

• Date :
• 0    
  0

Perioperative novel systemic immunotherapy-based approaches in urinary cancers

• Date :
• 0    
  0

COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF

• Date :
• 0    
  0

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer

• Date :
• 0    
  0

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

• Date :
• 0    
  0

FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020

• Date :
• 0    
  0

High-dose twice daily thoracic radiotherapy in limited disease small-cell lung cancer

• Date :
• 0    
  0

PARP inhibitors in prostate cancer: Choices of tests and how to test?

• Date :
• 0    
  0

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients

• Date :
• 0    
  0

Reducing damage to swallowing muscles during radiotherapy for head and neck cancers

• Date :
• 0    
  0

Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma

• Date :
• 0    
  0

Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

• Date :
• 0    
  0

HCRN GU16-260: Nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients

• Date :
• 0    
  0

Updated results from KEYNOTE-426 for metastatic kidney cancer

• Date :
• 0    
  0

Comment: JAVELIN-100 for metastatic urothelial cancer

• Date :
• 0    
  0

Highlights from ASCO 2020

• Date :
• 0    
  0

PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway

• Date :
• 0    
  0

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours

• Date :
• 0    
  0

ASCO 2020 prostate cancer highlights

• Date :
• 0    
  0

3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and neck

• Date :
• 0    
  0

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition

• Date :
• 0    
  0

Background of the KEYLYNK-007 trial for advanced solid tumours

• Date :
• 0    
  0

METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer

• Date :
• 0    
  0

Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients

• Date :
• 0    
  0

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer

• Date :
• 0    
  0

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk

• Date :
• 0    
  0

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma

• Date :
• 0    
  0

Perioperative chemotherapy with mfolfirinox vs gemcitabine/nab-paclitaxel for resectable

• Date :
• 0    
  0

New emerging treatment options and targeted therapies for bladder cancer

• Date :
• 0    
  0

CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC

• Date :
• 0    
  0

TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy

• Date :
• 0    
  0

KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal

• Date :
• 0    
  0

Timing of response to venetoclax combination treatment in older patients with acute myeloid

• Date :
• 0    
  0

ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer

• Date :
• 0    
  0

EAU guidelines for treating patients with advanced prostate cancer

• Date :
• 0    
  0

KRd vs VRd for initial therapy of newly diagnosed multiple myeloma

• Date :
• 0    
  0

Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19

• Date :
• 0    
  0

Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

• Date :
• 0    
  0

LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing

• Date :
• 0    
  0

Cumulative incidence of financial hardship in metastatic colorectal cancer patients

• Date :
• 0    
  0

Denosumab in multiple myeloma patients with renal insufficiency

• Date :
• 0    
  0

Association of BRCA alternations with response to PARP inhibitors in metastatic

• Date :
• 0    
  0

COM701 as a monotherapy and in combination with nivolumab for various advanced solid tumours

• Date :
• 0    
  0

Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma

• Date :
• 0    
  0

E2108: Systemic therapy plus early local therapy versus systemic therapy alone

• Date :
• 0    
  0

The paediatric precision oncology study INFORM: Clinical outcome and benefit for molecular

• Date :
• 0    
  0

Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chemotherapy

• Date :
• 0    
  0

KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy

• Date :
• 0    
  0

ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer

• Date :
• 0    
  0

Sym015 shows superior specificity compared to TKIs for NSCLC

• Date :
• 0    
  0

Update from KAITLIN for high-risk HER2-positive early breast cancer

• Date :
• 0    
  0

CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy

• Date :
• 0    
  0

Brigatinib for NSCLC, latest research and overcoming complications

• Date :
• 0    
  0

ASCO 2020: Pembrolizumab plus chemotherapy for patients with metastatic triple-negative

• Date :
• 0    
  0

Better genetic diagnostics in Ugandan breast cancer patients

• Date :
• 0    
  0

ASCO 2020: Updates in renal cancer

• Date :
• 0    
  0

CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma

• Date :
• 0    
  0

AGMT_MM-1: Investigating the oral microbiome in patients with relapsed/refractory multiple myeloma

• Date :
• 0    
  0

Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodkin lymphomavvvv

• Date :
• 0    
  0

KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advanced clear

• Date :
• 0    
  0

Association of gene expression with clinical outcomes in advanced RCC patients treated

• Date :
• 0    
  0

Renal cell cancer: Highlights from ASCO 2020

• Date :
• 0    
  0

FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory

• Date :
• 0    
  0

HERO: Relugolix versus leuprolide acetate for advanced prostate cancer

• Date :
• 0    
  0

44e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse

• Date :
• 4186    
  0

14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024

• Date :
• 3846    
  0

Post ASCO-ESMO 2024 Fédération Francophone de Cancérologie Digestive

• Date :
• 3178    
  0

45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024

• Date :
• 6931    
  0

Molecular Analysis for Precision Oncology Congress - MAP 2024

• Date :
• 2506    
  0